Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-04-02
1997-09-16
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 70, A61K 31445, C07D47104
Patent
active
056681410
ABSTRACT:
A tetracyclic compound of the formula: ##STR1## wherein A and the atoms to which it is attached comprise a pyridine ring selected from: ##STR2## wherein R.sup.1, R.sup.2, and R.sup.3 are specifically defined, which compounds are useful in the treatment of dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of substance abuse and other addictive behavior disorders, cognitive impairment and attention deficit disorder, and methods for the preparation thereof.
REFERENCES:
patent: 4282227 (1981-08-01), Brenner
patent: 4340600 (1982-07-01), Brenner et al.
patent: 5047536 (1991-09-01), Nichols
patent: 5420134 (1995-05-01), Nichols et al.
Sawaguchi et al., D1 Dopamine Receptors in Prefontal Cortex: Involvement in Working Memory; Feb. 1991, Science vol. 251.
Meltzer; Novel Approaches to the Pharmacotherapy of Schizophrenia; Drug Development Research 9:23-40 (1986).
Del Zompo, Dopamine Agonists in the Treatment of Schizophrenia; Progress in Brain Research vol. 65 (1986).
Levy; The Dopamine Theory OPF Attention Deficit Hyperactivity Disorder (ADHD) Australian and New Zealand Journal of Psychiatry 1991; 25:277-283.
Britton et al., Evidence for Involvement of Both D1 and D2 Receptors in Maintaining Cocaine Self-Administration, Parma Biochemistry & Behavior vol. 39, pp. 911-915 (1991).
Anderson et al., Thienopyridine Derivatives Identified as the First Selective, Full Efficacy, Dopamine D1 Receptor Agonists; European Journal of Pharmacology 137(1987) 291-292.
Kiguchi et al., A Route for Total Synthesis of Ergot Alkaloids Synthesis of the Desphyrrole Analogs of Methyl Lysergate, Isolysergol, and Isofumigtclavine A.; Heterocycles vol. 19, No. 10, 1982.
Effects of the D1 Agonist SKF-38393 Combined with Haloperidol in Schizophrenic Patients; Arch Gen Psychiatry vol. 47, Feb. 1990.
Muscat et al., Antidepressant-like effects of Dopamine Agonists in an Animal Model of Depression; Biol Psychiatry 1992;31:937-946.
Asin et al, Repeated D1 Receptor Agonist Treatment Blocks Cocaine-Induced Locomotor Activity and C-FOS Expression; Brain Research 637(1994) 342-344.
Reynolds, et al., Developments in the Drug Treatment of Schizophrenia; Trends in Pharmacological Sciences, 1992, 13(3), pp. 116-121.
Sibley et al., Molecular Biology of Dopamine Receptors; TIPS, 1992, 13(2) pp. 61-69.
Arnsten et al., Dopamine D1 Receptor Mechanisms in the Cognitive Performance of Young Adult and Aged Monkeys; Psychopharmacology (1994) 116:143-151.
Katz et al; Selective Effects of the D1 Dopamine Receptor Agonist, SKF 38393, on Behavior Maintained by Cocaine Injection in Squirrel Monkeys; Psychopharmacology (1992) 109;241-244.
Katerinopoulos et al., Structure Activity Relationships for Dopamine Analogs: A Review; Drugs of the Future vol. 12, No. 3 1987.
Lokhandwala; Preclinical and Clinical Studies on the Cardiovascular and Renal Effects of Fenoldopam a DA1 Receptor Agonist; Drug Devel. Research 10:123-134(1987).
Kaiser et al; Dopamine Receptors: Functions, Subtypes and Emerging Concepts; Medicinal Research Reviews vol. 5, No. 2, 145-229 (1985).
Wise et al, Brain Dopamine and Reward; Ann Rev. Psychol 1989 40:191-225.
Gu Yu Gui
Michaelides Michael
Shiosaki Kazumi
Abbott Laboratories
Browder Monte R.
Dahlen Garth M.
Ivy C. Warren
LandOfFree
Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-218491